A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics. / Almarsdóttir, Anna Birna; Björnsdóttir, Ingunn; Traulsen, Janine Morgall.

In: Health Policy, Vol. 71, No. 2, 02.2005, p. 233-41.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Almarsdóttir, AB, Björnsdóttir, I & Traulsen, JM 2005, 'A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics', Health Policy, vol. 71, no. 2, pp. 233-41. https://doi.org/10.1016/j.healthpol.2004.08.010

APA

Almarsdóttir, A. B., Björnsdóttir, I., & Traulsen, J. M. (2005). A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics. Health Policy, 71(2), 233-41. https://doi.org/10.1016/j.healthpol.2004.08.010

Vancouver

Almarsdóttir AB, Björnsdóttir I, Traulsen JM. A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics. Health Policy. 2005 Feb;71(2):233-41. https://doi.org/10.1016/j.healthpol.2004.08.010

Author

Almarsdóttir, Anna Birna ; Björnsdóttir, Ingunn ; Traulsen, Janine Morgall. / A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics. In: Health Policy. 2005 ; Vol. 71, No. 2. pp. 233-41.

Bibtex

@article{2b885c8b34904c46a967013b5b0ef38c,
title = "A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics",
abstract = "This study explores the lay view of pharmaceutical research and development--specifically pharmacogenomics. Forty-two persons participated in eight focus groups in Iceland. Participants were asked to comment on a future scenario consisting of predictions made by researchers concerning the consequences of the Human Genome Project over the next 40 years, and asked to give advice to politicians and the pharmaceutical industry. A dominating theme in the focus groups was the expectation that drugs developed based on pharmacogenomics will be more expensive than conventional mass produced drugs and concerns were voiced that this new technology would lead to inequalities locally and globally.",
keywords = "Adult, Aged, Drug Industry, Female, Focus Groups, Humans, Iceland, Male, Middle Aged, Pharmacogenetics, Journal Article, Research Support, Non-U.S. Gov't",
author = "Almarsd{\'o}ttir, {Anna Birna} and Ingunn Bj{\"o}rnsd{\'o}ttir and Traulsen, {Janine Morgall}",
year = "2005",
month = "2",
doi = "10.1016/j.healthpol.2004.08.010",
language = "English",
volume = "71",
pages = "233--41",
journal = "Health Policy",
issn = "0168-8510",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics

AU - Almarsdóttir, Anna Birna

AU - Björnsdóttir, Ingunn

AU - Traulsen, Janine Morgall

PY - 2005/2

Y1 - 2005/2

N2 - This study explores the lay view of pharmaceutical research and development--specifically pharmacogenomics. Forty-two persons participated in eight focus groups in Iceland. Participants were asked to comment on a future scenario consisting of predictions made by researchers concerning the consequences of the Human Genome Project over the next 40 years, and asked to give advice to politicians and the pharmaceutical industry. A dominating theme in the focus groups was the expectation that drugs developed based on pharmacogenomics will be more expensive than conventional mass produced drugs and concerns were voiced that this new technology would lead to inequalities locally and globally.

AB - This study explores the lay view of pharmaceutical research and development--specifically pharmacogenomics. Forty-two persons participated in eight focus groups in Iceland. Participants were asked to comment on a future scenario consisting of predictions made by researchers concerning the consequences of the Human Genome Project over the next 40 years, and asked to give advice to politicians and the pharmaceutical industry. A dominating theme in the focus groups was the expectation that drugs developed based on pharmacogenomics will be more expensive than conventional mass produced drugs and concerns were voiced that this new technology would lead to inequalities locally and globally.

KW - Adult

KW - Aged

KW - Drug Industry

KW - Female

KW - Focus Groups

KW - Humans

KW - Iceland

KW - Male

KW - Middle Aged

KW - Pharmacogenetics

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1016/j.healthpol.2004.08.010

DO - 10.1016/j.healthpol.2004.08.010

M3 - Journal article

C2 - 15607385

VL - 71

SP - 233

EP - 241

JO - Health Policy

JF - Health Policy

SN - 0168-8510

IS - 2

ER -

ID: 170601680